Screener
Pacira BioSciences, Inc. PCRX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028871
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Income before income taxes | 4,998 | 8,706 |
| Income tax expense | (2,082) | (3,894) |
| Net income | $2,916 | $4,812 |
| Net income per common share: | ||
| Basic and diluted net income per common share | $0.07 | $0.10 |
| Weighted average common shares outstanding: | ||
| Basic | 40,461 | 46,275 |
| Diluted | 40,910 | 46,526 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Pacira BioSciences, Inc.'s EPS (diluted)?
- Pacira BioSciences, Inc. (PCRX) reported EPS (diluted) of $0.07 in Q1 2026.
- How has Pacira BioSciences, Inc.'s EPS (diluted) changed year-over-year?
- Pacira BioSciences, Inc.'s EPS (diluted) decreased by 30.0% year-over-year, from $0.10 to $0.07.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Pacira BioSciences, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude